Inion Appoints Scott Pravda as President, Inion USA

Key new role to establish and build Inion's business in the USA completes senior management structure

Tampere, Finland and Guildford, UK. 2 July 2007… Inion Oy (LSE: IIN.L) ("Inion"), a company focused on the development of novel biodegradable medical implants, has appointed Scott Pravda as President, Inion USA, effective 9 July 2007.

Scott (42) will have the important role of building Inion's specialty orthopaedics trauma business in the USA, including recruiting key regional sales managers and establishing new distribution networks. This role is crucial to Inion's re-focused commercial strategy in which the US is regarded as the priority market.

Scott has an impressive track record of building successful sales organisations for medical device companies in the US. In 2000, he co-founded Hand Innovations, Inc., a manufacturer of fracture fixation products for the upper extremities (i.e. hand, wrist and elbow). As Chief Sales Officer, he was responsible for all company operations and established a sales organisation representing approximately 350 independent sales agents with a presence in all 50 US states. Hand Innovations was acquired by DePuy Orthopaedics (a Johnson & Johnson company) in 2006, when sales had grown from zero to $60 million annually.

Before this, Scott spent nearly ten years at Rehabilicare (formerly Medical Devices, Inc.), for which as Eastern Regional Sales Manager he established a sales team of 36 representatives covering 19 US states.

This key appointment follows closely that of Inion's new Chief Commercial Officer, David Follows, who is responsible for building the Company's commercial operations outside of North America. Furthermore, this appointment completes Inion's senior commercial management team and represents a significant milestone as highlighted in the Company's strategic review, completed earlier this year.

Chris Lee, Inion's Chief Executive Officer, commented: "We are very pleased that Scott has joined Inion in what is a key appointment for the company. We believe that his energy and experience in building effective and profitable sales operations in the US will be of great value to Inion as we work to realise the true commercial potential of our biodegradable implants in the dynamic orthopaedic trauma and spine surgery market segments. I am confident he will take our US business to a completely new level."

Scott Pravda, said: "I am really excited by this new opportunity. In the US, patients demand the latest technologies and access to the latest medical products. The US market therefore represents a major commercial opportunity for Inion. Based on my experience, I am confident that the company's biodegradable implant technology will be of great interest to surgeons, patients and healthcare payers alike and in time will become the products of choice in certain segments of the market."

Relocation of Inion UK Office

Inion also announces today that it has relocated its UK office to Guildford, Surrey. Contact details are as follows:

Inion Ltd
Surrey Technology Centre
40 Occam Road
The Surrey Research Park
Guildford
Surrey, GU2 7YG
United Kingdom

Tel: +44 (0)1483 685390

- ends -

For further information, please contact:

About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative biodegradable and bioactive implants in key target markets. The Company's target segments are Spine and Specialty Orthopaedics.

Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima[TM] family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation.
 
Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004. The Company has an office and an R&D facility in the UK and head office, R&D and production facilities in Tampere, Finland.
 
This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.